ARTICLE

FindCenter AddIcon

World-First Clinical Trial Explores Safety and Efficacy of DMT for Major Depression

By Ruairi J. Mackenzie — 2020

The world’s first clinical trial testing the efficacy of the psychedelic compound N,N-dimethyltryptamine (DMT) has won approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Read on www.technologynetworks.com

FindCenter Post-Image

Psychedelic Therapy and Racial Trauma: Offering Clients a Deeper Experience of Healing

Like most people of color in the United States, psychotherapist and researcher Monnica Williams has experienced myriad forms of racism. Early in her career, understanding its effects on her mind and body motivated her to help clients address their own racial trauma in therapy.

FindCenter AddIcon
FindCenter Post-Image

The Cost of Exclusion in Psychedelic Research

In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.

FindCenter AddIcon
FindCenter Post-Image

How Researchers and Advocates of Color Are Forging Their Own Paths in Psychedelic-Assisted Therapy

We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.

FindCenter AddIcon
FindCenter Post-Image

Psychedelics and Race: A Profile of Dr. Monnica T. Williams

The exuberant “renaissance” of studies researching psychedelic-assisted psychotherapy in the past twenty years has not sufficiently included the enrollment of racially diverse participants, a problem that psychedelic science and clinical research shares with mainstream psychiatry

FindCenter AddIcon

EXPLORE TOPIC

DMT